Baloxavir Marboxil Polymorphs: Investigating the Influence of Molecule Packing on the Dissolution Behavior

Baloxavir marboxil (BXM) is a new blockbuster FDA-approved anti-influenza virus agent. However, its poor solubility has limited its oral bioavailability. In this study, BXM was crystallized from several organic solvents, obtaining three polymorphs, and their dissolution behaviors were studied. Detai...

Full description

Bibliographic Details
Published in:	Crystals
Main Authors:	Xinbo Zhou, Kaxi Yu, Jiyong Liu, Zhiping Jin, Xiurong Hu
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Subjects:	baloxavir marboxil crystallization polymorphism crystal structure energy framework solubility
Online Access:	https://www.mdpi.com/2073-4352/12/4/550

Similar Items

Baloxavir Marboxil: An Original New Drug against Influenza
by: François Dufrasne
Published: (2021-12-01)

Validation of chromatographic method for impurity profiling of Baloxavir marboxil (Xofluza)
by: Wang Yiyun, et al.
Published: (2025-03-01)

Safety and effectiveness of baloxavir marboxil and oseltamivir for influenza in children: a real-world retrospective study in China
by: Xilin Ge, et al.
Published: (2024-07-01)

Efficacy of baloxavir marboxil as a prophylactic against influenza among in-patients and analysis of influenza virus mutations in their isolates at a Japanese hospital during the 2023–2024 flu season
by: Akihide Fujii, et al.
Published: (2025-03-01)

Clinical efficacy of baloxavir marboxil versus oseltamivir in kidney transplant recipients with influenza
by: Jiali Jiang, et al.
Published: (2025-07-01)

Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A
by: Chaochao Qiu, et al.
Published: (2024-04-01)

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system
by: Wei Wei, et al.
Published: (2024-07-01)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
by: Augustin Twabela, et al.
Published: (2020-12-01)

Determination of baloxavir marboxil in pharmaceutical preparations and spiked human plasma using its quenching action on acetoxymercuric fluorescein reagent: Assessment of greenness and whiteness
by: Mohamed S. Nasr, et al.
Published: (2024-06-01)

Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study
by: Jianpeng Cai, et al.
Published: (2024-07-01)

Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system
by: Yunsong Li, et al.
Published: (2024-05-01)

Safety evaluation of baloxavir marboxil: analysis and discussion utilizing real adverse events from the FAERS database
by: Xiaolong Lai, et al.
Published: (2025-05-01)

Ultrasensitive turn-off fluorescent sensor for estimation of the new influenza antiviral prodrug baloxavir marboxil in its pharmaceutical formulation
by: Amira S. Gouda, et al.
Published: (2025-01-01)

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
by: Vasiliy P. Mishin, et al.
Published: (2019-10-01)

Influenza A(H1N1)pdm09 Virus with Reduced Susceptibility to Baloxavir, Japan, 2024
by: Emi Takashita, et al.
Published: (2025-05-01)

Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses
by: Keita Fukao, et al.
Published: (2023-11-01)

Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014–2019/2020 seasons in Japan: an observational study
by: Jiaming Li, et al.
Published: (2023-03-01)

Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan
by: Nobuo Hirotsu, et al.
Published: (2023-01-01)

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
by: Keiichi Taniguchi, et al.
Published: (2022-01-01)

Fast and Efficient Synthesis of Racemic Baloxavir Catalyzed by Strong Solid Acid under Microwave Conditions
by: Yiyun Wang, et al.
Published: (2022-06-01)

Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials
by: Yu-Chi Kuo, et al.
Published: (2021-10-01)

Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China
by: Guichan Liao, et al.
Published: (2023-11-01)

Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States
by: Svenn Alexander Kommandantvold, et al.
Published: (2024-08-01)

Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report
by: Naonori Harada, et al.
Published: (2020-07-01)

Antiviral Treatment in Older Chinese Patient with SARS-CoV-2 and Influenza A Virus Co-Infection: A Case Series
by: Yang W, et al.
Published: (2023-07-01)

Impact of crystal polymorphism of rifaximin on dissolution behavior
by: Imen Toukabri, et al.
Published: (2024-03-01)

Influenza: state-of-the-art and vaccination during COVID-19 pandemic
by: Editorial Article
Published: (2021-06-01)

Drugs for Influenza Treatment: Is There Significant News?
by: Nicola Principi, et al.
Published: (2019-05-01)

Synthesis and Cap-Dependent Endonuclease Inhibition of Baloxavir Derivatives
by: Yiyun Wang, et al.
Published: (2023-06-01)

Low prevalence of influenza A strains with resistance markers in Brazil during 2017–2019 seasons
by: Thiago das Chagas Sousa, et al.
Published: (2022-09-01)

Antiviral Susceptibility of Swine-Origin Influenza A Viruses Isolated from Humans, United States
by: Rongyuan Gao, et al.
Published: (2024-11-01)

Prescription factors influencing baloxavir prescription during the 2018/2019 and 2019/2020 seasons: a administrative database study in Japan
by: Naomi Fujiwara, et al.
Published: (2023-02-01)

Co-Crystals of Resveratrol and Polydatin with L-Proline: Crystal Structures, Dissolution Properties, and In Vitro Cytotoxicities
by: Yijie Lou, et al.
Published: (2021-09-01)

Cost-Effectiveness Analysis of Influenza Treatments in Japan Using a Transmission Model: The Impact of Baloxavir and Oseltamivir Shares
by: Ataru Igarashi, et al.
Published: (2025-08-01)

Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism
by: Mai Han, et al.
Published: (2025-04-01)

Comparison of the efficacy and safety of baloxavir versus those of oseltamivir in pediatric patients with influenza: a meta-analysis
by: Sheng Chen, et al.
Published: (2025-10-01)

Investigation of Solubility Behavior of Canagliflozin Hydrate Crystals Combining Crystallographic and Hirshfeld Surface Calculations
by: Yefen Zhu, et al.
Published: (2021-01-01)

The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro
by: Xiaojia Guo, et al.
Published: (2024-09-01)

Genomic Analysis of Influenza A and B Viruses Carrying Baloxavir Resistance-Associated Substitutions Serially Passaged in Human Epithelial Cells
by: Brady T. Hickerson, et al.
Published: (2023-12-01)

Generation and Characterization of Drug-Resistant Influenza B Viruses Selected In Vitro with Baloxavir Acid
by: Amel Saim-Mamoun, et al.
Published: (2022-09-01)